The triple-negative subtype: New ideas for the poorest prognosis breast cancer

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 108-110

  Curigliano, Giuseppe ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; INIPARIB; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PROTEIN P53; RADIOSENSITIZING AGENT; SUNITINIB; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; TUMOR MARKER;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DNA REPAIR; DRUG TARGETING; GENE MUTATION; HUMAN; LOSS OF FUNCTION MUTATION; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MORTALITY; MUTATION; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DNA REPAIR; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEOADJUVANT THERAPY; PLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84855169753     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr038     Document Type: Article

References (24)

1. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295(21): 2492-2502.
2. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10(16): 5367-5374.
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003, 100(14): 8418-8423.
4. Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008, 14(24): 8010-8018.
5. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008, 26(8): 1275-1281.
6. Gaedcke J, Traub F, Milde S, et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol. 2007, 20(8): 864-870.
7. Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009, 115(2): 423-428.
8. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer. 1995, 72(4): 805-812.
9. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. J Natl Compr Canc Netw. 2009, 7(2): 122-192.
10. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003, 21(8): 1431-1439.
11. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008, 358(16): 1663-1671.
12. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007, 357(15): 1496-1506.
13. Veuger SJ, Curtin NJ, Smith GC, et al. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene. 2004, 23(44): 7322-7329.
14. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol. 2009, 27(18 suppl): 6s (Abstract 3).
15. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010, 376(9737): 235-244.
16. Slamon DJ, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. In: Paper presented at: the San Antonio Breast Cancer Symposium, December 8-11, 2005, San Antonio, TX. (Abstract 1).
17. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010, 28(7): 1145-1153.
18. Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatin- epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol. 2009, 20(4): 1185-1192.
19. Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol. 2008, 62(4): 667-672.
20. Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol. 2009, 27(15 suppl): 18s (Abstract 551).
21. Falo C, Moreno A, Varela M, et al. HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy. J Cancer Res Clin Oncol. 2007, 133(7): 423-429.
22. Cheang M, Chia SK, Tu D, et al. Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol. 2009, 27(suppl): 15s (Abstract 519).
23. Colleoni M, Cole BF, Viale G, et al. Classical CMF chemotherapy is more effective in selected breast cancer subtypes: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol. 2010, 28(18): 2966-2973.
24. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008, 26(11): 1810-1816.